✨ Onyx Summary A consortium led by Verily secured a two-year, $9.2 million renewal of the NIH System Biology award to advance FAIRplex, a platform enabling researchers to find, access, and analyze multimodal data from Accelerating Medicines Partnership (AMP®) projects. The renewal shifts FAIRplex from initial development to operational deployment
✨ Onyx Summary Geron Corporation granted stock options covering 320,000 shares to a newly hired employee as an inducement award, with options priced at the December 17, 2025 closing share price and vesting over four years in accordance with Nasdaq rules and the company’s inducement equity plan. FOSTER CITY,
✨ Onyx Summary Perspective Therapeutics announced that Chief Executive Officer Thijs Spoor will present at the J.P. Morgan Healthcare Conference on January 14, 2026, in San Francisco. SEATTLE, Dec. 18, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering
✨ Onyx Summary Kyverna Therapeutics priced an underwritten public offering of 13.33 million shares at $7.50 per share, generating expected gross proceeds of approximately $100 million, with an option for underwriters to purchase up to an additional 2.0 million shares. The offering, led by J.P. Morgan, Leerink
✨ Onyx Summary Legend Biotech Corporation announced that CEO Ying Huang will present a company update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, with a live webcast and replay available via the company’s investor relations website. SOMERSET, N.J.,Dec. 17, 2025 – Legend Biotech
✨ Onyx Summary ImmunityBio reported long-term Phase 2/3 QUILT-3.032 data showing that ANKTIVA plus BCG delivered durable disease-free, progression-free, and disease-specific survival, with high cystectomy avoidance through 36 months in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer. Published in The Journal of Urology, the findings extend evidence
✨ Onyx Summary nChroma Bio said it has received regulatory clearance in Hong Kong to initiate a Phase 1/2 clinical trial of CRMA-1001 for the treatment of chronic hepatitis B. The approval advances a novel epigenetic silencing approach into the clinic, positioning the company to address a large unmet global
✨ Onyx Summary Kyverna Therapeutics announced the launch of an underwritten public offering of $100 million of common stock, with an option for underwriters to purchase up to an additional $15 million of shares, subject to market conditions. The financing is intended to be conducted under Kyverna’s existing shelf registration
✨ Onyx Summary Kyverna Therapeutics reported positive topline data from the registrational Phase 2 KYSA-8 trial showing that mivocabtagene autoleucel (miv-cel), a CD19-targeting CAR T-cell therapy, delivered statistically significant and sustained improvements in mobility, disability, and stiffness in patients with stiff person syndrome after a single dose. The results support Kyverna’
✨ Onyx Summary Kyverna Therapeutics announced it will host a live webcast and conference call on December 15, 2025, to review topline results from the registrational Phase 2 KYSA-8 trial evaluating KYV-101 in patients with stiff person syndrome. EMERYVILLE, Calif., Dec. 14, 2025 – Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical
✨ Onyx Summary The European Medicines Agency recommended granting conditional marketing authorization for ImmunityBio’s ANKTIVA in combination with BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, marking a potential new treatment option where cystectomy is often the only alternative. The recommendation, based on durable complete
✨ Onyx Summary Guardant Health and Trial Library formed a strategic collaboration to integrate precision oncology diagnostics with AI-driven trial matching and navigation to expand access to cancer clinical trials across the United States. The partnership links Guardant’s large-scale biomarker and real-world data with Trial Library’s nationwide clinic network
✨ Onyx Summary Geron Corporation announced a strategic restructuring plan that will reduce its workforce by approximately one-third and is expected to lower full-year 2026 operating expenses below 2025 levels, with savings beginning in the first quarter of 2026. The move reflects a shift toward tighter financial discipline while maintaining focus
✨ Onyx Summary Sinaptica Therapeutics received funding from the Centre for Aging + Brain Health Innovation (CABHI), in partnership with Baycrest, to support development and validation of its personalized, non-invasive neuromodulation system for Alzheimer’s disease. The funding deepens Sinaptica’s collaboration with Baycrest and supports advancement toward clinical readiness and future
✨ Onyx Summary Ocugen said CEO and co-founder Dr. Shankar Musunuri will present at the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, where he will discuss the company’s modifier gene therapy platform and its potential applications in inherited retinal and age-related blindness diseases. The presentation, alongside investor
✨ Onyx Summary Lexicon Pharmaceuticals announced the publication of preclinical data in the Journal of the Endocrine Society validating Acyl-CoA Synthetase 5 (ACSL5) as a therapeutic target for obesity and chronic weight management, supporting advancement of its investigational oral inhibitor LX9851. The findings, combined with Lexicon’s March 2025 worldwide licensing
